$ONCO 8-K/A SEC Filings

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

On September 18, 2024, the Company received formal notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s securities were subject to delisting due to (i) the Company’s non-...

CFO CONSULTING AGREEMENT dated as of June 10, 2024 (this “Agreement”), between Onconetix Inc. (a Delaware Corporation), (the “Company”), and Karina M. Fedasz (the “Consultant”).

We hereby consent to the incorporation by reference in Onconetix, Inc.’s (i) Registration Statements on Form S-8 (Nos. 333-268357, 333-265843 and 333-276824), (ii) Registration Statement on Form S-3 (No. 333-270383, 333-267142 and 333-26...

We have audited the accompanying balance sheets of Proteomedix AG (the “Company”) as of December 31, 2022 and 2021, the related statements of loss and comprehensive loss, stockholders’ deficit, and cash flows for each of the two years in...

This section describes the material provisions of the Share Exchange Agreement (as defined below) but does not purport to describe all of the terms thereof. The following summary is qualified in its entirety by reference to the complete ...